Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 227

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 227
---
 exercisable, with a weighted average exercise price of $ 3,555.83, and a weighted average remaining contractual term of 7.2years. There was nounrecognized compensation expense related to the outstanding stock options as of March 31, 2025. F-37

Stock-Based Compensation Expense

For the three months ended March 31, 2025
and 2024, the Company recorded stock-based compensation expense for the periods indicated as follows:

| General and administrative:                                 |     | Three Months Ended 
 March 31,          
 2025               |         |     | 2024 |        |
|:------------------------------------------------------------|:----|:-------------------|--------:|:----|:-----|-------:|
| RSA awards                                                  |     | $                  | 189,348 |     | $    |      — |
| RSU awards                                                  |     |                    |       — |     |      | 22,383 |
| Stock Options                                               |     |                    |       — |     |      |  7,215 |
| General and administrative stock-based compensation expense |     |                    | 189,348 |     |      | 29,598 |
| Research and development:                                   |     |                    |         |     |      |        |
| RSA awards                                                  |     |                    |  34,107 |     |      |      — |
| RSU awards                                                  |     |                    |       — |     |      |  1,898 |
| Stock Options                                               |     |                    |       — |     |      |    598 |
| Research and development stock-based compensation expense   |     |                    |  34,107 |     |      |  2,496 |
| Total stock-based compensation expense                      |     | $                  | 223,455 |     | $    | 32,094 |

As of March 31, 2025, there was approximately $
of unrecognized stock-based compensation expense related to RSA grants. The unrecognized stock-based compensation expense is expected
to be recognized over a period of year for the RSA grants.

9. Warrants Class C Common Stock Warrants As of March 31, 2025, the Company has 232,360outstanding Class C Common Stock Warrants to purchase up to 485shares of common stock with a exercise price of $ 16.00, which expire on February 14, 2028. The Class C Common Stock Warrants, which were